Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

893
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
893
Esophageal Varices-I: Introduction01:24

Esophageal Varices-I: Introduction

2.4K
Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
2.4K
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.5K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.5K
Peptic Ulcer Disease III: Clinical Manifestations and Complications01:25

Peptic Ulcer Disease III: Clinical Manifestations and Complications

71
Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant...
71
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.9K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.9K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct Skin Penetration and Immune Responses to Ionic and Nanoparticulate Cobalt in Allergic Contact Dermatitis.

Allergy·2026
Same author

[Acute abdomen-Rare cause in an 80-year-old female patient under immunosuppressive treatment].

Innere Medizin (Heidelberg, Germany)·2023
Same author

Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer.

ESMO open·2022
Same author

[COVID-19 and endoscopy services].

Der Gastroenterologe : Zeitschrift fur Gastroenterologie und Hepatologie·2022
Same author

Status quo after one year of COVID-19 pandemic in otolaryngological hospital-based departments and private practices in Germany.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2021
Same author

[Hemoptysis and acute kidney injury in COVID-19].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2020

Related Experiment Video

Updated: May 6, 2026

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
04:00

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension

Published on: November 15, 2024

1.1K

[Gastrointestinal bleeding in cardiological patients].

G Braun1, H Messmann

  • 1III. Medizinische Klinik, Klinikum Augsburg, Stenglinstr. 2, 86156, Augsburg, Deutschland, georg.braun@klinikum-augsburg.de.

Medizinische Klinik, Intensivmedizin Und Notfallmedizin
|October 24, 2013
PubMed
Summary

Gastrointestinal bleeding from anticoagulants like rivaroxaban and dabigatran requires specific management. This study outlines a standard operating procedure for treating severe GI bleeding during these therapies.

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

23.0K
Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices
04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

1.8K

Related Experiment Videos

Last Updated: May 6, 2026

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension
04:00

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension

Published on: November 15, 2024

1.1K
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

23.0K
Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices
04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

1.8K

Area of Science:

  • Internal Medicine
  • Pharmacology
  • Gastroenterology

Context:

  • Oral anticoagulation and antiplatelet therapies increase the risk of gastrointestinal (GI) bleeding.
  • Lower GI bleeding is associated with poorer patient outcomes.
  • Newer anticoagulants like dabigatran and rivaroxaban present management challenges for bleeding complications.

Purpose:

  • To establish a standard operating procedure (SOP) for managing severe GI bleeding associated with rivaroxaban, dabigatran, and antiplatelet therapy.
  • To provide guidance on treating bleeding complications during anticoagulant and antiplatelet therapy.

Summary:

  • Phenprocoumon-related bleeding should be managed with prothrombin complex concentrates and vitamin K1.
  • Drug concentrations of dabigatran and rivaroxaban can indicate bleeding risk.
  • Severe bleeding from dabigatran or rivaroxaban warrants prothrombin complex therapy; antiplatelet-related bleeding requires platelet transfusion.
  • Low-dose aspirin should be resumed after 24 hours post-bleeding event.

Impact:

  • Provides a clear management protocol for severe GI bleeding in patients on novel oral anticoagulants and antiplatelet agents.
  • Aims to improve patient outcomes by standardizing treatment for life-threatening GI bleeds.
  • Facilitates consistent and effective care for complex bleeding scenarios in clinical practice.